Welcome to the Exeter Clinical Laboratory International website
NHS logo

Cholinesterase

Blood Sciences Test


Specimen

EDTA preferred, serum acceptable

Units

u/L

Test Usage

Cholinesterases are enzymes that hydrolyze the acetylcholine released at central and peripheral sites. Two types of cholinesterase are present; acetylcholinesterase, or true cholinesterase, and pseudocholinesterase. Acetylcholinesterase is found in large amounts in red cells and neurons. Pseudocholinesterase (PCHE) is present in serum, plasma, liver, pancreas, heart, and other tissues. Pseudocholinesterase is also known as butrylcholinesterase (BuChE) or plasmacholinesterase.

Other Cholinesterase levels are reduced in chronic liver disease, renal disease,
pregnancy/oestrogens, acute illness.

Both plasma and tissue cholinesterase activity are markedly inhibited by organophosphate pesticides and herbicides, such as diazinon and malathion. Acetylcholinesterase is theoretically the best enzyme to follow because its presence in red cells more accurately reflects enzyme concentration in the central nervous system. However, plasma PCHE can be measured more easily and is suppressed enough to be useful in diagnosis of acute organophosphate toxicity. PCHE levels correlate fairly well with cholinergic signs. Headache and fatigue are common in mild poisoning in which PCHE activity is inhibited 20 to 50%. Weakness, muscle fasciculation, and difficulty talking are symptomatic of moderate poisoning, in which PCHE activity is reduced 80 to 90%. In severe poisoning, when enzyme activity is inhibited more than 90%, patients present with coma, flaccid paralysis, and cyanosis.

Pregnancy and liver disease can also cause a decrease in cholinesterase activity. Caution must be exercised when diagnosing pesticide or herbicide intoxication in the presence of these conditions.

PCHE is also useful to evaluate patients who have experienced prolonged apnoea after exposure to succinylcholine, a muscle relaxant used in surgery. Normally, cholinesterase rapidly hydrolyzes succinylcholine. Less than < 1% of individuals have either atypical or Kalow variants that do not hydrolyze succinylcholine efficiently. Individuals, who are either homozygotes or compound heterozygotes, have very low levels of pseudocholinesterase activity that is not inhibited by dibucaine. These patients may develop prolonged muscle relaxation and apnoea after the administration of succinylcholine.

Availability

Referred test

Turnaround Time

28 days

Can be added on to an existing request up to 4 days following sample receipt

Assayed By

Sendaway (Southmead Hospital Contact Roberta Goodall 0117 959 6083 for interpretation)

Specimen Labelling Procedure
University of Exeter logo
UKAS Medical logo

8210

Royal Devon University Healthcare logo